Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers
Nephrology Dialysis Transplantation · 2026
DOI: 10.1093/ndt/gfaf187 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Young Su Joo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Calcitriol, Proteinuria, Renin-Angiotensin System. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Hanmi Pharmaceutical, Seoul, Korea.
Abstract (Originalsprache)
Background
Patients with immunoglobulin A nephropathy (IgAN) and moderate proteinuria are at risk of progressive renal failure despite the maximal use of renin–angiotensin system blockers (RASBs). This study evaluated the efficacy of active vitamin D in reducing proteinuria in patients with IgAN receiving RASBs.
Methods
In this double-blind, placebo-controlled trial, we enrolled biopsy-confirmed patients with IgAN and persistent proteinuria (0.5–3.5 g/day) after maximal use of RASBs. Patients were randomized to receive either 0.25 μg/day of calcitriol or placebo for 12 months. The primary outcomes were the change in the mean urinary protein:creatinine ratio (UPCR) and daily urinary protein excretion during the treatment.
Results
A total of 138 patients from six medical centres were enrolled and assigned to receive a placebo (n = 69) or 0.25 μg of calcitriol (n = 69) and 115 patients (83.3%) completed the study. The calcitriol group showed a greater reduction in geometric means of UPCR {mean difference −187 mg/g [95% confidence interval (CI) −370.6 to −4.0], P = .04} and urinary albumin:creatinine ratio [−162 mg/g (95% CI −290.9 to −34.6), P = .01] than placebo. Changes in daily urinary protein excretion were −3.5% (from 1.32 to 1.02 g/day) in the control group and −13.1% (from 1.29 to 0.97 g/day) in the calcitriol group, without any statistically significant differences (P = .11). The annual decrease of the estimated glomerular filtration rate (eGFR) was −0.32 ml/min/1.73 m2 (95% CI −2.54 to 1.99) in the calcitriol group and −3.64 ml/min/1.73 m2 (95% CI −5.70 to −1.58) in the placebo group (calcitriol versus placebo over time, P = .02). Adverse events were comparable between the groups.
Conclusion
The addition of 0.25 μg/day calcitriol to RASBs safely lowered residual proteinuria and slowed the eGFR decline in patients with IgAN, suggesting a potential therapeutic role for calcitriol in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea.
- Division of Nephrology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
- Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea.
- Department of Internal Medicine, National Health Insurance Service Medical Center, Ilsan Hospital, Goyang, Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
ORCID-Profile: Young Su Joo, Tae-Ik Chang, Dong Ki Kim, Seung Hyeok Han, Tae-Hyun Yoo
Förderung
- Hanmi Pharmaceutical, Seoul, Korea
Zitieren
APA
Joo, Y. S., Chang, T. I., Kim, D. K., Han, S. H., Kang, S. W., & Yoo, T. H. (2026). Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf187
Vancouver
Joo YS, Chang TI, Kim DK, Han SH, Kang SW, Yoo TH. Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfaf187
BibTeX
@article{Joo2026,
author = {Joo, Young Su and Chang, Tae-Ik and Kim, Dong Ki and Han, Seung Hyeok and Kang, Shin-Wook and Yoo, Tae-Hyun},
title = {Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfaf187}
}
EUVIMED